|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Surface Oncology, Inc. (SURF) |
|
|
$1.07 0.00 (0.00%) as of 4:30 Thu 9/7
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
54,611,000 |
| Market
Cap: |
58.43(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.57 - $1.08 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Surface Oncology is an immuno-oncology company focused on using its knowledge of the biological pathways crucial to the immunosuppressive tumor microenvironment (TME) for the development of cancer therapies. NZV930 and SRF617 are antibodies inhibiting cluster of differentiation (CD) 73 and CD39, respectively, and illustrate how Co.'s knowledge of TME biology can be utilized across programs. SRF388 is an antibody targeting interleukin 27, an immunosuppressive cytokine, or protein that is overexpressed in certain cancers, including hepatocellular, lung and renal cell carcinoma. GSK4381562 is an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
37,090 |
68,266 |
| Total Sell Value |
$0 |
$0 |
$34,864 |
$88,487 |
| Total People Sold |
0 |
0 |
4 |
6 |
| Total Sell Transactions |
0 |
0 |
4 |
9 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fees Jessica |
Chief Financial Officer |
• – – |
2023-09-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(101,915) |
0 |
|
- |
|
| Adams Chandra |
Deputy GC |
• – – |
2023-09-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(23,884) |
0 |
|
- |
|
| Grayzel David S. |
Director |
– • – |
2023-09-08 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,945,453) |
0 |
|
- |
|
| Goater Jeff |
Director |
– • – |
2023-09-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(129,222) |
0 |
|
- |
|
| Oneill Alison |
Chief Medical Officer |
• – – |
2023-09-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(56,686) |
0 |
|
- |
|
| Sigal Charles Elliott |
Director |
– • – |
2023-09-08 |
4 |
D |
$0.00 |
$0 |
I/I |
(45,453) |
0 |
|
- |
|
| Ross Robert W. |
Chief Executive Officer |
• • – |
2023-09-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(83,193) |
0 |
|
- |
|
| Palombella Vito J. |
Chief Scientific Officer |
• – – |
2023-09-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(87,212) |
0 |
|
- |
|
| Rath Henry C. |
Chief Business Officer |
• – – |
2023-09-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(44,971) |
0 |
|
- |
|
| Oneill Alison |
Chief Medical Officer |
• – – |
2023-08-01 |
4 |
S |
$0.94 |
$6,619 |
D/D |
(7,042) |
56,686 |
|
-13% |
|
| Adams Chandra |
Deputy GC |
• – – |
2023-08-01 |
4 |
S |
$0.94 |
$3,667 |
D/D |
(3,901) |
30,899 |
|
-13% |
|
| Ross Robert W. |
Chief Executive Officer |
• – – |
2023-08-01 |
4 |
S |
$0.94 |
$15,710 |
D/D |
(16,713) |
83,193 |
|
-13% |
|
| Fees Jessica |
Chief Financial Officer |
• – – |
2023-08-01 |
4 |
S |
$0.94 |
$8,868 |
D/D |
(9,434) |
101,915 |
|
-13% |
|
| Adams Chandra |
Deputy GCOfficer |
• – – |
2022-10-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
34,800 |
|
-47% |
|
| Oneill Alison |
Chief Medical Officer |
• – – |
2022-08-03 |
4 |
S |
$1.72 |
$7,676 |
D/D |
(4,463) |
63,728 |
|
52% |
|
| Ross Robert W. |
Chief Executive Officer |
• – – |
2022-08-03 |
4 |
S |
$1.72 |
$18,222 |
D/D |
(10,594) |
99,906 |
|
52% |
|
| Fees Jessica |
Chief Financial Officer |
• – – |
2022-08-03 |
4 |
S |
$1.72 |
$10,286 |
D/D |
(5,980) |
111,349 |
|
52% |
|
| Palombella Vito J. |
Chief Scientific Officer |
• – – |
2022-08-03 |
4 |
S |
$1.72 |
$7,676 |
D/D |
(4,463) |
87,212 |
|
52% |
|
| Rath Henry C. |
Chief Business Officer |
• – – |
2022-08-03 |
4 |
S |
$1.72 |
$9,763 |
D/D |
(5,676) |
32,324 |
|
52% |
|
| Fees Jessica |
Chief Financial Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
38,000 |
117,329 |
|
- |
|
| Oneill Alison |
Chief Medical Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
38,000 |
68,191 |
|
- |
|
| Ross Robert W. |
Chief Executive Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
56,000 |
110,500 |
|
- |
|
| Rath Henry C. |
Chief Business Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
38,000 |
38,000 |
|
- |
|
| Palombella Vito J. |
Chief Scientific Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
38,000 |
91,675 |
|
- |
|
| Oneill Alison |
Chief Medical Officer |
• – – |
2021-07-21 |
4 |
S |
$6.10 |
$90,335 |
D/D |
(14,809) |
30,191 |
|
15% |
|
102 Records found
|
|
Page 1 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
